Arbutus Biopharma Corp (ABUS)
Healthcare
Biotechnology
4.30 $
-1.6%
vs. previous close
Closing price · As of: 31. Jul 2026
Arbutus Biopharma Corp (ABUS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Operating Cash Flow" came in at -8.1 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
| Tick rows to compare them in a chart (up to 4) | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -20 | -22 | -17 | -19 | -15 | -21 | -10 | -13 | -16 | -5.8 | -4.7 | -8.1 | -34 | |
| 0.3 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| 3.0 | 2.5 | 1.7 | 2.0 | 3.2 | 2.2 | 1.6 | 3.6 | 0.9 | 1.3 | 1.3 | 1.4 | 4.7 | |
| 1.6 | – | – | – | – | – | – | – | – | – | – | – | – | |
| -4.0 | -3.4 | 1.5 | -2.9 | 2.8 | -2.5 | -0.2 | 5.3 | -18 | 1.2 | 1.8 | -179 | -194 | |
| 0.9 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 8.1 | 8.1 | |
| 1.4 | 10 | 22 | 12 | 9.8 | -12 | 13 | 11 | 16 | -10 | -1.4 | 2.2 | 6.4 | |
| 4.7 | 1.7 | 3.8 | 24 | 24 | 1.8 | 1.4 | 2.8 | 0.5 | 0.8 | 1.6 | 12 | 15 | |
| -13 | -9.7 | 8.8 | 17 | 20 | -31 | 4.5 | 0.7 | 0.3 | -15 | -4.4 | 5.7 | -13 | |
| -20 | -22 | -17 | -19 | -15 | -21 | -10 | -13 | -16 | -5.8 | -4.7 | -8.1 | -34 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.